Corcept Therapeutics Incorporated CORT
81.93 USD +1.47 (+1.83%)
At closeNov 3, 2026, 4:02 PM EST
81.93 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
80.92 Day range 84.19
28.66 52-week range 126.38
- YTD
- +135.43%
- 1 year
- +10.46%
Analyst view
Consensus: buy
Buy
Price target (mean) 141.00 +72.1% upside
Now 81.93
- Target (low)
- 50.00
- Target (mean)
- 141.00
- Target (high)
- 165.00
Ratings (0m) 5 4 buy · 0 hold · 1 sell
- Strong buy1
- Buy3
- Hold0
- Sell1
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.84 | 0.74 – 1.03 | 0.16 | +425.0% | 336.37M | +62.0% | 4 |
| Next quarter | 1.17 | 1.01 – 1.31 | 0.20 | +486.3% | 388.75M | +92.3% | 4 |
| Current year | 2.12 | 1.84 – 2.41 | 0.82 | +158.5% | 1.15B | +50.5% | 4 |
| Next year | 4.20 | 1.85 – 6.86 | 2.12 | +98.0% | 1.68B | +46.2% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 30, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Jul 30, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 29, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 27, 2026 | Wolfe Research | Downgrade | Peer Perform | Underperform |
| May 28, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| May 28, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 13, 2026 | UBS | Upgrade | Neutral | Buy |
| May 4, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 1, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 26, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 26, 2026 | Wolfe Research | Upgrade | Underperform | Peer Perform |
| Mar 25, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 25, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 20, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 23, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jan 23, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 2, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jan 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 16, 2025 | UBS | Initiated | — | Neutral |
| Nov 25, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 18, 2025 | Wolfe Research | Initiated | — | Peer Perform |
| Oct 20, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 10, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 25, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 10, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 1, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 1, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| May 6, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |